Objectives: To determine the efficacy of two a1-adrenoceptor antagonists with different affinities for a1-adrenoceptor subtypes, silodosin and naftopidil, in the treatment of premature ejaculation. Methods: This was a prospective, open-label, multicenter trial. A total of 26 patients with untreated acquired premature ejaculation were enrolled. Premature ejaculation was defined based on the International Society for Sexual Medicine recommendation. Patients self-administered on demand silodosin 4 mg or naftopidil 25 mg 1 h before intercourse, alternating drugs at least three times each. Clinical global impression change for premature ejaculation, premature ejaculation profile, and intravaginal ejaculation latency time were evaluated at baseline and during treatment. Results: Due to clinical global impression change, 24 patients (92%) and 12 patients (46%) reported improvement in their own premature ejaculation problems under silodosin and nafitopidil administration, respectively. Silodosin treatment produced a significantly higher improvement rate compared with naftopidil (P = 0.0002). Objectively, silodosin significantly prolonged intravaginal ejaculation latency time compared with baseline and naftopidil (P < 0.01). Mean intravaginal ejaculation latency times were 1.9, 4.1, and 7.6 min at baseline, control and with silodosin, respectively. The rate of reduced semen volume during silodosin treatment was higher than during naftopidil treatment. There were no adverse systemic effects in either group. Conclusions: Silodosin, a highly selective a1A-adrenoceptor antagonist, produces greater improvements in premature ejaculation profiles and related symptoms along with intravaginal ejaculation latency time in acquired premature ejaculation patients with or without erectile dysfunction. This result supports the clinical use of silodosin as an alternative treatment for premature ejaculation.
Introduction
PE is a common sexual problem that significantly impacts QOL of patients and their partners through lower satisfaction with sexual intercourse and negative personal consequences. 1 This significant problem affects not only young men, but also middle-aged and older men with other QOL diseases, such as LUTS and ED. [1] [2] [3] [4] [5] Thus treatment of PE restored the QOL of men and their partners in a wide range of age groups.
Recent advances in pharmacological treatment for PE have provided us with new evidence regarding dapoxetine, tramadol, and lidocaine and/or prilocaine. 1, 6, 7 Among these therapeutic options, a-blockers attract attention as alternative treatment choices, because of their suppressive actions for contractions of the seminal vesicle, vas deferens and prostate, and related muscles are direct peripheral effector organs to induce projectile ejaculation. [7] [8] [9] [10] These peripheral effector organs should be considered as a new target for treating premature ejaculation. In this context we have focused on a-blockers. They have different pharmacological actions depending on their subtype selectivity. We identified treatment of PE with silodosin, a highly selective a1A-AR antagonist and a strong inhibitor of ejaculation, after preliminary studies showed a favorable effect on PE. 8, [11] [12] [13] To obtain more clinical evidence for further development of alternative options for PE treatment, we compared the efficacy of silodosin with that of naftopidil, which is the weakest suppressant of ejaculation among the a1-blockers depending on their subtype selectivity. 14 
Methods
The present trial was a prospective, open-label, multicenter study, carried out in accordance with the ethical principles of the Declaration of Helsinki, and approved by the ethics committee of each department. All patients provided written informed consent.
Patients with PE that met the ISSM recommendations (Appendix S1) were enrolled in this study. 1 All patients could achieve vaginal penetration with or without PDE5-Is when enrolled. They had sexual intercourse regularly. Patients with psychiatric diseases, chronic prostatitis or receiving other a1-blockers, SSRIs, other psychiatric drugs (antidepressants, antianxiety) or sex hormones were excluded. A total of 27 patients satisfied the inclusion and exclusion criteria. According to recent ISSM criteria, enrolled patients included one life-long and 26 acquired PE patients. In the present study, we excluded the one life-long PE patient to unify the etiology of PE. Subsequently, 26 acquired PE patients were analyzed.
Ejaculatory profiles with the PEP and IELT were evaluated before treatment as the baseline condition (Fig. 1) . 15 All patients took silodosin 4 mg or naftopidil 25 mg 1 h before intercourse, alternating at least three times for each drug. The time of taking the medicine was decided according to peaks of plasma drug concentrations, although there is a difference in the half-life periods of the drugs. During the treatment period, erectile and ejaculatory conditions, and IELT were recorded at each intercourse. IELT was measured by the patient using a watch (not a stopwatch). The mean IELT during the treatment period was applied as a post-treatment value. IELT refers to the time between the start of vaginal intromission and the start of intravaginal ejaculation or sense of orgasm. After the treatment period, ejaculatory profiles with PEP items and patients' satisfaction with the treatment by CGIC in PE, 16 and semen volume and ejaculation-related problems during treatment were evaluated for both agents. The question of the CGCI is as follows: Compared with the start of the study, would you describe your premature ejaculation problems as. . .? As the primary end-point of the present study, we compared three categories of the answers (much better or better, slightly better and no change or worse) of the CGIC for PE in two drugs treatment. Much better or better, and slightly better were categorized as an improvement by treatment. The rate of patients who felt reduced semen volume or complete loss of projectile ejaculation (anejaculation) and ejaculation-related problems during treatment were evaluated by the same questionnaires applied in a previous study. 17 We informed the patient about reduced semen volume or anejaculation as a possible adverse effect before starting the trial.
The results of ejaculatory status and the changes of parameters were tested using Student's t-test and the v 2 -test. Statistical analysis was carried out using Stat View 5.0 for Windows (SAS Institute, Cary, NC, USA).
Results

Patient characteristics
A total of 26 patients with acquired PE and a mean age of 50.7 years (range 21-76 years), who reported having had PE for an average of 6.0 years (range 1-18 years) were tested. Of these patients, 11 (42.3%) suffered from ED and had been treated with PDE5-Is before participating in this study.
Treatment efficacy
CGIC
As a primary subjective end-point, improved personal problems as a result of the CGIC, 24 patients (92.3% CI 0.78-0.97) and 12 patients (46.1% CI 0.24-0.64) reported that their own PE problems improved under silodosin and naftopidil administration, respectively. Silodosin treatment produced a significantly higher improvement rate compared with naftopidil treatment (P = 0.0002; Fig. 2 ).
Premature ejaculation profile
Ejaculation control: A significant improvement of ejaculatory control occurred with both drugs compared with baseline (P < 0.01; Fig. 3a ). Silodosin significantly improved ejaculation control compared with naftopidil (P < 0.01).
Satisfaction with sexual intercourse: Silodosin significantly improved sexual intercourse satisfaction compared with the baseline and naftopidil (P < 0.01; Fig. 3b ).
Recording IELT and ejaculatory conditions Ejaculation-related personal distress: Silodosin significantly reduced ejaculation-related personal distress compared with that at baseline. However, there was no significant difference in ejaculation-related personal distress between silodosin and naftopidil (Fig. 4a ).
Difficulty in relationship with partner: Silodosin did not affect relationship difficulties with the partner compared with the baseline and naftopidil (Fig. 4b) .
IELT
As an objective finding obtained from all IELT after each sexual intercourse, the mean IELT during silodosin treatment was significantly longer than those at baseline and during naftopidil treatment (P < 0.01; Table 1 ).
Changes of semen volume and distress
Changes of semen volume A total of 13 patients (50%) reported much decreased or "absence of ejaculation" (no projected ejaculation with orgasm) with silodosin administration. Silodosin significantly reduced semen volume compared with naftopidil (P = 0.01; Fig. 5 ).
Distress as a result of decreased semen volume
Distress as a result of decreased semen volume during silodosin treatment was relatively higher than with naftopidil, but not significantly (Table 2 ). Of patients with much decreased or no projectile ejaculation with silodosin (n = 13), seven (54%) felt significant distress. However, another six patients (46%) were not distressed significantly about decreased semen volume (Table 2) .
Systemic adverse events
No symptomatic adverse events, such as postural hypotension, were reported.
Discussion
PE is a common sexual disorder. However, it is poorly understood for its epidemiology and etiology. The impact of PE on patients' QOL is significant. Men who suffered from PE were more likely to show low satisfaction for sexual intercourse. Furthermore PE negatively affected self-confidence and the relationship with the partner, and caused mental distress. Despite the serious psychological and QOL influence of PE, few men seek treatment, because evidencebased effective treatments remain limited. 1 Daily or ondemand SSRI and topical local anesthetics (lidocaine and/or prilocaine as a cream, gel or spray) are the basis for today's pharmacotherapy. 1, 6, 7 With this background, silodosin showed greater improvements in PE profiles and related symptoms along with IELT in acquired PE patients with or without ED compared with naftopidil. The present study suggested the clinical feasibility of silodosin as an alternative option for PE treatment the same as our preliminary 8 and other studies.
9,10
Additionally, current findings confirmed the roles of a1A-AR subtypes on ejaculation, and would extend the clinical window for treatment of PE. Silodosin is a third-generation a1-blocker, which is specifically selective for the a1A-AR subtype. 18 Naftopidil is an a1-blocker with a threefold greater affinity for the human a1D-AR subtype. 19 The selectivity for a1A-AR subtypes is associated with improved patterns of urinary voiding and storage functions. Previous well-designed studies in human volunteers clearly showed that silodosin acts on the seminal vesicle, vas deferens and prostate through its selectivity of a a1A-AR. 13 Contraction of the seminal vesicles (and prostate) is modulated by adrenergic nerves, specifically, depending on the activity of the a1A-AR. The a1A-AR comprises 75% among the distribution of a1-AR subtypes in the seminal vesicle. 20 Consequently, silodosin has a strong suppressive action on seminal emission through its high a1A selectivity. The trigger for projectile ejaculation is increasing pressure in the prostatic urethra as a result of seminal emission. Therefore, suppression or delay of seminal emission might prolong ejaculation latency and provide better ejaculatory control compared with naftopidil with its lower a1A selectivity. The findings in the present study suggest that silodosin should be considered as a new target-oriented therapy for PE, which affects the contractile function of the seminal vesicles, vas deferens, prostate and urethra directly in contrast to current pharmacological treatments. 10, 13, 20 An additional merit of silodosin treatment is its safety and availability. Silodosin is available worldwide for use in LUTS. In the present study, there were no systemic adverse events, and given its regular clinical use for LUTS, silodosin is clearly a safe drug even for elderly populations. 11, 12 A weak point of silodosin treatment is its reversible reduction of semen volume. In the current study, 50% of patients reported significantly decreased semen volume (very decreased/not at all) under silodosin treatment. For those patients complaining of reduced semen volume, we tried reducing the dose of silodosin. So far, 2 mg silodosin has restored semen volume and good satisfaction for sexual intercourse (unpubl. data). Although only a limited number of patients (n = 4) have been treated, it seems we can manage reduced semen volume by dose reduction. Furthermore, half of the patients experiencing reduced semen volume were not distressed by the episode as same as our previous pilot study. 8 Lengthened sexual intercourse as a result of extended IELT might increase sexual satisfaction for the patient and partner even if some of them had reduced semen volume, in contrast to the normal volunteers study. 17 In addition, reduced semen volume is a reversible effect. Semen volume is recovered when patients stop taking silodosin. 13 Some limitations to this study exist. The first limitation was the small sample size, which was confined to acquired PE patients only. In addition, 42% of patients that had ED that were managed by PDE5-Is before enrollment to the study. These facts showed that patients who seek treatment for PE are varied and do not necessarily have life-long PE, and frequently have PE combined with ED. 2, 5 At the present point in Japan, PE is not been well recognized as a medical condition that is treatable. Subsequently, only limited patients were able to be enrolled in the present study, although the latent population who suffer from PE seems to be significant. 5, 21 It is necessary to increase the knowledge of PE as a common sexual condition as well as ED. The second limitation to the present study was the non-use of a stopwatch for measurements of IELT. Despite the potential advantage of an objective measurement, stopwatches have the disadvantage of being intrusive and potentially disruptive of sexual pleasure or spontaneity. 22, 23 Thus, it was quite difficult to apply a stopwatch in this study with the limited PE patients. The third limitation was the comparison between single doses of each drug. There is a possibility that the modulation of dosage of drugs could alter efficacy and adverse effects. In addition, the impact of demographic variables (education level, marital status and income), comorbidity count and age decade on the effects of the drugs were not clarified. For analysis with more stratified data, more numbers of patients would be required.
However, with the results of CGIC for PE as our primary end-point, PEP and IELT clearly represented a significant improvement of PE-related problems. The current result might have clinical significance, although limited numbers of patients were analyzed. A study with larger numbers of patients and including life-long PE is a future task.
In conclusion, the present study clearly showed a significant difference in the efficacy of two a1-AR antagonists with different affinity for a1-AR subtypes, silodosin and naftopidil, in the treatment of PE. Silodosin significantly improved PE and its related problems more than naftopidil. The present study provided us with additional clinical evidence for a new treatment concept for PE by a highly selective a1A-AR antagonist, silodosin. 
